OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies
Stocks in this Quantisnow insightHealth Care
Historical context for OSTX
Across the 11 sessions after earlier OSTX headlines, the stock closed higher 6 times and lower 4 times, with a median move of 5.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | OSTX | SPY |
|---|---|---|---|
| Feb 2, 2026 | OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | +2.2% | +0.5% |
| Jan 15, 2026 | OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | -5.8% | +0.3% |
| Jan 14, 2026 | OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary | +0.6% | -0.5% |
| Jan 12, 2026 | OS Therapies Enters into Warrant Inducement Agreements | -7.1% | +0.2% |
| Jan 5, 2026 | OS Therapies Provides First Half 2026 Corporate Outlook | +7.5% | +0.7% |
| Dec 15, 2025 | OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | -7.7% | -0.2% |
Keep researching OSTX
Quantisnow market dataAMEX
OSTX
OS Therapies Incorporated
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Get push alerts for OSTX
Full OSTX profile on Quantisnow Follow OSTX and get a push notification the moment its next story breaks.